Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Eli Lilly and Company continued its deal-making in the cardiovascular/metabolic space on 31 October by acquiring certain rights that Beam Therapeutics Inc. had obtained in a 2019 licensing agreement with fellow Cambridge, MA, biotech Verve Therapeutics, Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?